![]() |
市場調查報告書
商品編碼
1520495
2024-2032 年按設備類型、應用(冠狀動脈疾病、心律不整、心臟衰竭等)、最終用戶和地區分類的心血管設備市場報告Cardiovascular Devices Market Report by Device Type, Application (Coronary Artery Disease, Cardiac Arrhythmia, Heart Failure, and Others), End User, and Region 2024-2032 |
IMARC Group年全球心血管器材市場規模達589億美元。介入性心臟病學手術的引入,加上有利的報銷政策,正在刺激市場成長。
主要市場驅動力:心臟衰竭、冠狀動脈疾病、心律不整等心血管疾病的數量不斷增加,正在推動市場發展。此外,消費者越來越傾向於採用微創取代傳統心臟直視手術,以加速復健速度、減少住院時間、提高病患舒適度等,這也是另一個重要的成長誘導因素。
主要市場趨勢:3D 列印和人工智慧 (AI) 技術的不斷進步導致先進心血管設備的推出,以提供更高的精度和安全性,這是刺激整個市場的新興趨勢之一。
地理趨勢:發達的醫療基礎設施正在支撐北美市場。除此之外,主要醫療器材製造商的存在以及研發活動投資的增加進一步對區域市場產生正面影響。
競爭格局:根據心血管設備市場概況,全球市場上的一些知名公司包括雅培實驗室、B. Braun Melsungen AG、百多力、波士頓科學公司、佳能醫療系統公司、康德樂健康公司、愛德華生命科學公司、通用電氣公司、LivaNova PLC、美敦力 PLC、西門子 Healthineers GmbH (Siemens AG) 和泰爾茂心血管系統公司 (Terumo Corporation) 等。
挑戰與機會:心血管設備的推出涉及複雜的工程和先進材料的整合,這可能會阻礙市場的成長。然而,關鍵參與者正在確保這些設備(尤其是植入式設備)的長期可靠性和安全性。反過來,這將在未來幾年繼續擴大全球市場。
對微創手術的需求
人們的偏好從傳統的心臟直視手術轉向侵入性較小的方法,以最大限度地縮短恢復時間、降低手術風險、改善患者的治療效果等,這正在刺激市場。例如,2024 年 4 月,由戈爾韋大學研究小組監督的 FAST TRACK CABG 研究首次測試了一種為患者規劃、指導和進行心臟搭橋手術的新方法。它證明了基於人工智慧的血流掃描的非侵入性心臟CT是可行且安全的。除此之外,機器人技術和即時成像技術的廣泛採用有助於準確放置瓣膜、支架和其他設備,而無需大切口,這也提高了心血管設備市場收入。例如,2024 年 2 月,飛利浦推出了 LumiGuide,它採用光纖 RealShape (FORS) 技術,用於無輻射、微創手術。除此之外,微創手術是使用專門的心血管儀器和先進的成像技術透過小切口進行的,從而可以進行有針對性的精確治療。一些常見的例子包括經導管二尖瓣修復術 (TMVR)、經導管主動脈瓣置換術 (TAVR)、內視鏡靜脈採集等。例如,2022 年12 月,全球領先的醫療保健公司之一雅培(Abbott) 宣布推出新型經導管主動脈瓣植入(TAVI) 系統Navitor,適用於印度患有嚴重主動脈瓣狹窄且手術風險極高或極高的患者。隨著技術的進步,這些手術變得更加有效和安全,從而擴大採用它們來治療多種心血管疾病。例如,2024 年 5 月,根據心血管造影和介入學會 (SCAI) 年會上公佈的一年新資料,Anteris Technologies 開發的新型仿生經導管主動脈瓣置換術 (TAVR) 系統可以為心臟科醫生提供治療嚴重主動脈瓣狹窄(AS)的新方法。
引入增強型變異體
心血管設備在慢性心臟病和中風的治療、診斷和管理中發揮著至關重要的作用。因此,主要參與者正在推出新穎的設備,使醫療保健專業人員能夠準確評估心血管疾病的嚴重程度、監測患者的心臟健康狀況、改進有效的治療方法等。患者數量正在不斷增加智慧支架、植入式心律調節器、除顫器等的普及,這反過來又對心血管設備市場前景產生正面影響。例如,2023年12月,Terumo India宣布推出Ultimaster Nagomi,這是一種藥物洗脫支架,旨在用於治療冠狀動脈疾病。除此之外,為引進改良的心血管設備(包括心律調節器)而對研發活動的投資不斷增加,也是重要的成長誘導因素。例如,2023年5月,心律管理領域的全球開發商之一微創公司的多種植入式心律調節器Alizea和Celea獲得FDA批准。此外,它們還具有 AutoMRI 模式,這是 MicroPort 發明的演算法,可提高接受 MRI 檢查的患者的安全性。同樣,2023 年 7 月,雅培宣布 FDA 批准其無引線心律調節器系統 Aveir DR。此外,機器學習和人工智慧用於分析大量心血管資料,以個性化治療計劃、預測患者結果、提高診斷準確性等。美國梅奧診所表示,具有人工智慧功能的數位聽診器可以改善圍產期心肌病變的診斷,圍產期心肌病變是一種可能危及生命的疾病,會削弱女性在懷孕期間的心肌功能。
策略夥伴關係
知名公司、醫療器材製造商、研究機構和醫療保健組織正在合作並進行併購活動,以引進心血管設備,包括精確成像工具。這是心血管設備市場近期的機會之一。例如,2023 年 9 月,領先的心臟資料管理平台之一 PaceMate 宣布與 MedAxiom 合作,在單一雲端原生環境中為心臟和 EHR資料創建工作流程解決方案。據此,2023年10月,GE醫療保健與波士頓科學公司合作開發增強型心臟影像系統。此外,這些合作夥伴關係還可以幫助公司應對複雜的監管環境,並利用合作夥伴的當地專業知識和已建立的分銷網路進入國際市場。例如,2023 年 6 月,飛利浦與 Biotronik 建立合作夥伴關係,擴大飛利浦 SymphonySuite 客戶可用的心血管設備範圍。除此之外,2023 年 5 月,PaceMate 與 AliveCor 合作,AliveCor 是 FDA 批准的個人心電圖技術和遠端病患管理解決方案的全球領導者之一,涵蓋植入式心臟裝置。
IMARC Group提供了每個細分市場的主要趨勢分析,以及 2024-2032 年全球、區域和國家層面的心血管器材市場預測。我們的報告根據設備類型、應用程式和最終用戶對市場進行了分類。
診斷和監測設備
心電圖(ECG)
遠端心臟監測
其他
治療及手術設備
心律管理 (CRM) 設備
導管
支架
心臟瓣膜
其他
治療和手術設備是最受歡迎的設備類型
該報告根據設備類型對市場進行了詳細的細分和分析。這包括診斷和監測設備(心電圖 (ECG) 遠端心臟監測等)以及治療和手術設備(心律管理 (CRM) 設備、導管、支架、心臟瓣膜等)。根據該報告,治療和手術設備佔最大的部分。
旨在治療心血管疾病的外科手術和治療干預措施的數量不斷增加正在推動該領域的成長。此外,治療和手術設備包括植入式心臟復律去顫器(ICD)、支架、心律調節器、導管、心臟瓣膜、心室輔助裝置(VAD)等。提供機械循環支持等。例如,2023 年 12 月,全球醫療保健技術領導者之一美敦力公司 (Medtronic plc) 宣布 FDA 批准 PulseSelect 脈衝場消融 (PFA) 系統用於治療陣發性和持續性心房顫動 (AF)。與此一致,2023年6月,Magenta Medical啟動了一項世界上最小的心臟幫浦的可行性研究,可減少心臟手術期間的血管通路併發症。
冠狀動脈疾病 (CAD)
心律不整
心臟衰竭
其他
冠狀動脈疾病(CAD)主導心血管設備市場佔有率
該報告根據應用程式提供了詳細的市場細分和分析。這包括冠狀動脈疾病(CAD)、心律不整、心臟衰竭等。根據該報告,冠狀動脈疾病(CAD)代表了最大的市場區隔。
用於治療、診斷和管理冠狀動脈疾病的 CAD 設備正在各國廣泛關注。此外,診斷設備的廣泛採用,如血管內超音波 (IVUS) 設備、血管攝影系統和電腦斷層血管攝影 (CTA) 機,有助於評估冠狀動脈阻塞的嚴重程度,正在推動市場發展。例如,2022年8月,美敦力宣佈在獲得CE標誌批准後推出其新型藥物洗脫冠狀動脈支架Onyx Frontier藥物洗脫支架(DES)。除此之外,2024 年 1 月,致力於創建心臟病診斷新護理標準的公司之一 Cleerly 推出了 Cleerly ISCHEMIA,該產品最近獲得了美國食品和藥物管理局 (FDA) 510(k) 醫療器械許可。 Cleerly ISCHEMIA 分析軟體是一種基於機器學習的自動化決策支援工具,專為接受冠狀動脈電腦斷層血管攝影 (CCTA) 的患者而設計。
醫院
專科診所
其他
醫院佔據整體市場佔有率的大部分
該報告提供了基於最終用戶的詳細市場細分和分析。這包括醫院、專科診所等。報告稱,醫院佔最大部分。
醫院是心血管設備的主要最終使用者。他們提供廣泛的心臟服務,例如心血管疾病的治療、診斷和外科手術。醫院擁有心導管實驗室和專門的心臟科,配備先進的影像系統和手術室,這提高了心血管設備市場的近期價格。例如,2024 年 1 月,安大略省衛生部長西爾維亞瓊斯宣佈在加拿大基奇納的聖瑪麗總醫院建立一個新的心臟實驗室,以幫助心臟病患者。他們需要一系列全面的設備,例如植入設備、診斷設備、手術器械、監測系統等,這正在推動這一細分市場的成長。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美在市場上表現出明顯的主導地位
市場研究報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美是心血管設備最大的市場。
包括中風和周邊動脈疾病在內的心血管疾病的盛行率不斷上升,正在推動該區域市場的發展。例如,根據加拿大心臟和中風基金會2022年2月發布的報告,有75萬名患者被診斷出心臟衰竭。此外,有利的報銷政策和快速的監管批准也是重要的成長誘導因素。例如,2023 年 9 月,CorVista Health 宣布 FDA 批准其用於檢測心臟病是否存在的非侵入性醫療設備系統。與此一致,2024年1月,專注於結構性心臟病的瑞典醫療器材公司Occlutech的ASD封堵器獲得美國FDA批准,用於治療心房中隔缺損(ASD)。除此之外,根據心血管設備市場統計,無線心電圖的引入可以實現即時患者監測和診斷。反過來,這將在未來幾年繼續刺激區域市場。例如,2021年2月,VivaLNK開發了一款穿戴式心電圖監測解決方案,旨在在六分鐘步行測試(6MWT)期間無線捕捉心電圖和心率。
主要參與者正在大力投資研發,以開發創新的心血管設備。他們專注於提高設備性能、耐用性和患者治療效果。研發工作旨在引進先進技術,例如微創手術、遠端監控系統和個人化醫療方法。此外,心血管設備市場公司不斷推出新的心血管設備以擴大其產品組合。這些發布通常涉及具有改進功能和增強功能的下一代設備。他們優先考慮解決未滿足的臨床需求,例如針對特定心血管疾病的新療法或提供更高精度和易用性的設備。除此之外,主要參與者、醫療保健提供者和研究機構之間的合作和夥伴關係在心血管設備市場上很常見。這些合作促進創新,促進知識交流,並利用集體專業知識和資源來開發新技術和解決方案並將其商業化。
雅培實驗室
貝朗梅爾松根股份公司
百多力
波士頓科學公司
佳能醫療系統公司
康德樂健康公司
愛德華茲生命科學公司
通用電氣公司
利瓦諾瓦公司
美敦力公司
西門子醫療有限公司 (Siemens AG)
泰爾茂心血管系統株式會社(泰爾茂株式會社)
(請注意,這只是關鍵參與者的部分列表,報告中提供了完整列表。)
2024 年 5 月:根據心血管造影與介入學會 (SCAI) 年會上公佈的一年新資料,Anteris Technologies 開發的新型仿生經導管主動脈瓣置換術(TAVR) 系統可以為心臟科醫生提供一種新方法治療嚴重主動脈瓣狹窄(AS)。
2024 年 5 月:根據《npj Fexible Electronics》雜誌上發表的文章,來自中國的研究團隊提出了一種使用穿戴式感測器評估血管年齡和心血管疾病的新方法。
2024 年 4 月:由戈爾韋大學研究小組監督的 FAST TRACK CABG 研究首次測試了一種為患者規劃、指導和進行心臟搭橋手術的新方法。
2024 年1 月:印度美敦力私人有限公司(India Medtronic Private Limited) 宣布與Cardiac Design Labs (CDL) 進行策略合作,以擴大、推出和擴大對CDL 的新型診斷技術Padma Rhythms 的使用,Padma Rhythms 是一種外部循環記錄器(ELR) 貼片,專為長期和慢性疾病而設計。
The global cardiovascular devices market size reached US$ 58.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 98.6 Billion by 2032, exhibiting a growth rate (CAGR) of 5.8% during 2024-2032. The introduction of interventional cardiology procedures, coupled with favorable reimbursement policies, are stimulating the market growth.
Major Market Drivers: The increasing number of cardiovascular conditions, such as heart failure, coronary artery disease, arrhythmias, etc., is propelling the market. Moreover, the rising consumer inclination towards minimally invasive alternatives to traditional open-heart surgeries for faster recovery, reduced hospital stays, improved patient comfort, etc., is also acting as another significant growth-inducing factor.
Key Market Trends: The growing advancements in 3D printing and artificial intelligence (AI) technologies that are leading to the launch of advanced cardiovascular devices to offer enhanced precision and safety are among the emerging trends stimulating the overall market.
Geographical Trends: The well-developed healthcare infrastructures are bolstering the market in North America. Apart from this, the presence of major medical device manufacturers and the elevating investments in R&D activities are further positively influencing the regional market.
Competitive Landscape: According to the cardiovascular devices market overview, some of the prominent companies across the global market include Abbott Laboratories, B. Braun Melsungen AG, Biotronik, Boston Scientific Corporation, Canon Medical Systems Corporation, Cardinal Health Inc., Edwards Lifesciences Corporation, General Electric Company, LivaNova PLC, Medtronic PLC, Siemens Healthineers GmbH (Siemens AG), and Terumo Cardiovascular Systems Corporation (Terumo Corporation), among many others.
Challenges and Opportunities: The launch of cardiovascular devices involves complex engineering and integration of advanced materials, which can hamper the market growth. However, key players are ensuring the long-term reliability and safety of these devices, particularly those that are implantable. This, in turn, will continue to augment the global market in the coming years.
Demand for Minimally Invasive Procedures
The shifting preferences of individuals from traditional open-heart surgeries toward less invasive methodologies that minimize recovery times, reduce surgical risks, improve patient outcomes, etc., are stimulating the market. For example, in April 2024, the FAST TRACK CABG study, overseen by a team of researchers at the University of Galway, tested a new approach to the planning, guidance, and conducting of heart bypass surgery on patients for the first time. It demonstrated that non-invasive cardiac CT with AI-powered blood flow scanning is feasible and safe. Besides this, the widespread adoption of robotics and real-time imaging techniques facilitates the accurate placement of valves, stents, and other devices without the need for large incisions, which is also elevating the cardiovascular devices market revenue. For instance, in February 2024, Philips introduced LumiGuide, which is powered by Fiber Optic RealShape (FORS) technology, for radiation-free, minimally invasive surgeries. Apart from this, minimally invasive procedures are performed via small incisions using specialized cardiovascular instruments and advanced imaging techniques, which allow for targeted and precise treatments. Some of the common examples include transcatheter mitral valve repair (TMVR), transcatheter aortic valve replacement (TAVR), endoscopic vein harvesting, etc. Consequently, they are gaining traction across the globe. For example, in December 2022, Abbott, one of the leading global healthcare companies, announced the launch of its novel transcatheter aortic valve implantation (TAVI) system, Navitor, for individuals in India with severe aortic stenosis who are at high or extreme surgical risk. As technology advances, these procedures are becoming more effective and safer, thereby leading to their increasing adoption in treating numerous cardiovascular conditions. For instance, in May 2024, according to new one-year data presented at the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI), a new biomimetic transcatheter aortic valve replacement (TAVR) system developed by Anteris Technologies can offer cardiologists with a new way to treat severe aortic stenosis (AS).
Introduction of Enhanced Variants
Cardiovascular devices play a crucial role in the treatment, diagnosis, and management of chronic heart conditions and stroke. Consequently, key players are launching novel devices that enable healthcare professionals to accurately assess the severity of cardiovascular diseases, monitor the heart health of patients, improve effective therapies, etc. Moreover, the increasing number of patients requiring intervention to address their cardiovascular conditions is escalating the popularity of smart stents, implantable pacemakers, defibrillators, etc. This, in turn, is positively influencing the cardiovascular devices market outlook. For example, in December 2023, Terumo India announced the launch of Ultimaster Nagomi, a drug-eluting stent intended for use in the treatment of coronary artery disease. Besides this, the growing investments in R&D activities to introduce improved cardiovascular devices, including pacemakers, are acting as significant growth-inducing factors. For instance, in May 2023, MicroPort, one of the global developers in the field of cardiac rhythm management, received FDA approval for its wide range of implantable pacemakers, Alizea and Celea. Additionally, they feature AutoMRI mode, an algorithm invented by MicroPort, that increases the safety of patients who are undergoing an MRI examination. Similarly, in July 2023, Abbott announced the FDA approval of its leadless pacemaker system, Aveir DR. Furthermore, machine learning and AI are employed for analyzing vast amounts of cardiovascular data to personalize treatment plans, predict patient outcomes, improve diagnostic accuracies, etc. For example, in January 2024, research led by Dr. Demilade Adedinsewo, one of the cardiologists at the Mayo Clinic in the U.S., suggested that the AI-enabled digital stethoscope could improve the diagnosis of peripartum cardiomyopathy, a potentially life-threatening condition that weakens the heart muscle of women during pregnancy.
Strategic Partnerships
Prominent companies, medical device manufacturers, research institutions, and healthcare organizations are collaborating and entering into mergers and acquisitions activities to introduce cardiovascular devices, including precise imaging tools. This represents one of the cardiovascular devices market recent opportunities. For instance, in September 2023, PaceMate, one of the leading cardiac data management platforms, announced the partnership with MedAxiom to create workflow solutions for cardiac and EHR data in a single, cloud-native environment. In line with this, in October 2023, GE HealthCare collaborated with Boston Scientific to develop enhanced cardiac imaging systems. Additionally, these partnerships aid companies in navigating complex regulatory landscapes and gaining access to international markets by leveraging the local expertise and established distribution networks of their partners. For example, in June 2023, Philips entered into a partnership with Biotronik to expand the range of cardiovascular devices available for Philips SymphonySuite customers. Besides this, in May 2023, PaceMate collaborated with AliveCor, one of the global leaders in FDA-cleared personal electrocardiogram technology and remote patient management solutions, to encompass implantable cardiac devices.
IMARC Group provides an analysis of the key trends in each segment of the market, along with the cardiovascular devices market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on the device type, application, and end user.
Diagnostic and Monitoring Devices
Electrocardiogram (ECG)
Remote Cardiac Monitoring
Others
Therapeutic and Surgical Devices
Cardiac Rhythm Management (CRM) Devices
Catheter
Stents
Heart Valves
Others
Therapeutic and surgical devices is the most popular device type
The report has provided a detailed breakup and analysis of the market based on the device type. This includes diagnostic and monitoring devices (electrocardiogram (ECG) remote cardiac monitoring, and others) and therapeutic and surgical devices (cardiac rhythm management (CRM) devices, catheter, stents, heart valves, and others). According to the report, therapeutic and surgical devices represent the largest segment.
The increasing number of surgical procedures and therapeutic interventions aimed at treating cardiovascular diseases is propelling the segment's growth. Moreover, therapeutic and surgical devices include implantable cardioverter defibrillators (ICDs), stents, pacemakers, catheters, heart valves, ventricular assist devices (VADs), etc. They aid in regulating heart rhythm, restoring blood flow, providing mechanical circulatory support, etc. Consequently, they are gaining extensive traction as less invasive alternatives to traditional open-heart surgeries, which is elevating the cardiovascular devices market demand. For example, in December 2023, Medtronic plc, one of the global leaders in healthcare technologies, announced the FDA approval of the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). In line with this, in June 2023, Magenta Medical launched a feasibility study for the world's smallest heart pump that reduces vascular access complications during heart surgery.
Coronary Artery Disease (CAD)
Cardiac Arrhythmia
Heart Failure
Others
Coronary artery disease (CAD) dominates the cardiovascular devices market share
The report has provided a detailed breakup and analysis of the market based on the application. This includes coronary artery disease (CAD), cardiac arrhythmia, heart failure, and others. According to the report, coronary artery disease (CAD) represented the largest market segmentation.
CAD devices used for treatment, diagnosis, and management of coronary artery disease condition are gaining traction across countries. Moreover, the widespread adoption of diagnostic devices, such as intravascular ultrasound (IVUS) devices, angiography systems, and computed tomography angiography (CTA) machines, as they help in assessing the severity of coronary artery blockages, is propelling the market. For example, in August 2022, Medtronic announced the launch of its novel drug-eluting coronary stent, the Onyx Frontier drug-eluting stent (DES), following CE Mark approval. Besides this, in January 2024, Cleerly, one of the companies working to create a new standard of care for the diagnosis of heart disease, introduced Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance. Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool specifically designed for patients undergoing coronary computed tomography angiography (CCTA).
Hospitals
Specialty Clinics
Others
Hospitals account for the majority of the overall market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.
Hospitals are the primary end users of cardiovascular devices. They provide a wide range of cardiac services, such as treatment, diagnosis, and surgical procedures for cardiovascular diseases. Hospitals have cardiac catheterization labs and specialized cardiology departments equipped with advanced imaging systems and surgical suites, which is increasing the cardiovascular devices market's recent price. For instance, in January 2024, Sylvia Jones, the health minister of Ontario, announced the development of a new cardiac lab at St. Mary's General Hospital in Kitchener, Canada, to help cardiac patients. They require a comprehensive range of devices, such as implantable devices, diagnostic equipment, surgical instruments, monitoring systems, etc., which is driving the growth in this segmentation.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest market for cardiovascular devices.
The increasing prevalence of cardiovascular conditions, including stroke and peripheral artery disease, is propelling the regional market. For instance, as per the report published by the Heart and Stroke Foundation of Canada in February 2022, there were 750,000 patients diagnosed with heart failure. Moreover, favorable reimbursement policies and fast regulatory approvals are acting as significant growth-inducing factors. For example, in September 2023, CorVista Health announced the FDA approval of its non-invasive medical device system that is used for detecting the presence of cardiac disease. In line with this, in January 2024, Occlutech, a Swedish medical device company focused on structural heart disease, received the U.S. FDA approval for its ASD Occluder for the treatment of atrial septal defects (ASDs). Apart from this, as per the cardiovascular devices market statistics, the introduction of wireless ECG has allowed for real-time patient monitoring and diagnosis. This, in turn, will continue to stimulate the regional market in the coming years. For example, in February 2021, VivaLNK developed a wearable ECG monitoring solution designed to wirelessly capture ECG and heart rate during a six-minute walk test (6MWT).
The key players are investing significantly in R&D to develop innovative cardiovascular devices. They focus on improving device performance, durability, and patient outcomes. R&D efforts aim to introduce advanced technologies, such as minimally invasive procedures, remote monitoring systems, and personalized medicine approaches. Additionally, cardiovascular devices market companies are continuously launching new cardiovascular devices to expand their product portfolios. These launches often involve next-generation devices with improved features and enhanced capabilities. They are prioritizing addressing unmet clinical needs, such as novel therapies for specific cardiovascular conditions or devices that offer improved precision and ease of use. Besides this, collaborations and partnerships between key players, healthcare providers, and research institutions are common in the cardiovascular devices market. These collaborations foster innovation, facilitate knowledge exchange, and leverage collective expertise and resources to develop and commercialize new technologies and solutions.
Abbott Laboratories
B. Braun Melsungen AG
Biotronik
Boston Scientific Corporation
Canon Medical Systems Corporation
Cardinal Health Inc.
Edwards Lifesciences Corporation
General Electric Company
LivaNova Plc
Medtronic Plc
Siemens Healthineers GmbH (Siemens AG)
Terumo Cardiovascular Systems Corporation (Terumo Corporation)
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: According to new one-year data presented at the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI), a new biomimetic transcatheter aortic valve replacement (TAVR) system developed by Anteris Technologies can offer cardiologists with a new way to treat severe aortic stenosis (AS).
May 2024: According to the article published in the journal npj Fexible Electronics, a team of researchers from China presented a novel approach to use wearable sensors for assessing vascular age and cardiovascular diseases.
April 2024: The FAST TRACK CABG study, overseen by a team of researchers at the University of Galway, tested a new approach to the planning, guidance, and conducting of heart bypass surgery on patients for the first time.
January 2024: India Medtronic Private Limited announced a strategic collaboration with Cardiac Design Labs (CDL) to scale up, launch, and expand access to CDL's novel diagnostic technology, Padma Rhythms, an external loop recorder (ELR) patch designed for long-term and comprehensive heart monitoring and diagnosis.